Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

18.16 -0.22

Overview

Share price change

24h

Current

Min

18.03

Max

18.58

Key metrics

By Trading Economics

Income

-607K

-51M

Sales

-28M

100M

EPS

-0.46

Profit margin

-51.215

Employees

1,784

EBITDA

4.1M

-44M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+68.6% upside

Dividends

By Acuity

Next Earnings

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-279M

2.1B

Previous open

18.38

Previous close

18.16

News Sentiment

By Acuity

100%

0%

322 / 340 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 lip 2026, 23:56 UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

29 lip 2026, 23:56 UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

29 lip 2026, 23:56 UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

29 lip 2026, 23:52 UTC

Social Media
News

Robinhood Markets reported record Q2 revenue of $1.31 billion but shares are lower in after-market trading due to a drop in cryptocurrency revenue and revised expense outlook.

29 lip 2026, 23:51 UTC

Social Media
Correlated Moves
News

Hecla Mining reported positive Q2 exploration results, extending high-grade mineralization at Keno Hill and Midas. Shares are higher in after-market trading.

29 lip 2026, 23:51 UTC

Social Media
News

PennyMac Mortgage Investment Trust's Q2 EPS of $0.23 missed estimates, with revenue at $73 million. Shares are trading lower in after-market hours.

29 lip 2026, 23:51 UTC

News

Five9 Inc will join the S&P SmallCap 600 index, effective August 3, 2026. Shares are higher in after-market trading following the announcement.

29 lip 2026, 23:51 UTC

News

General Motors Co shares declined in after-market hours as Ford's strong earnings and guidance overshadowed its outlook amid broader market pressures.

29 lip 2026, 23:51 UTC

Social Media
News

American Water Works reported strong Q2 earnings and revenue but shares declined slightly in after-market hours, reflecting broader market trends.

29 lip 2026, 23:46 UTC

Social Media
News

DoorDash Inc launches DoorDash Air, a new drone delivery unit. Shares are higher in after-market trading, continuing recent upward momentum.

29 lip 2026, 23:46 UTC

News

Avis Budget Group reported second-quarter earnings below expectations, with revenue at $3 billion and EPS of $0.98. Shares are lower in after-market hours.

29 lip 2026, 23:46 UTC

News
Correlated Moves

Entegris Inc. announced board changes, with Bertrand Loy retiring in 2026. Shares are higher in after-market hours, reflecting a broader Nasdaq 100 increase.

29 lip 2026, 23:41 UTC

News

Claros Mortgage Trust reported a second-quarter net loss of $255.4 million, contributing to a decline in after-market trading. Shares are lower.

29 lip 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

29 lip 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

29 lip 2026, 23:41 UTC

News

Churchill Downs shares fell after reporting Q2 adjusted EPS of $3.45, slightly missing estimates, and announcing plans to explore property sales.

29 lip 2026, 23:41 UTC

Social Media
News

Meta Platforms reported second-quarter earnings below expectations, with net income declining to $15.85 billion. Shares fell sharply in after-market trading amid rising costs.

29 lip 2026, 23:41 UTC

Social Media
News

Qualcomm Inc shares fell in after-market trading following weaker-than-expected guidance and a profit decline in its third-quarter fiscal 2026 results.

29 lip 2026, 23:41 UTC

Social Media
News

Modine Manufacturing reported first-quarter net income of $73.9 million, but shares declined in after-market trading following mixed results and revenue that missed estimates.

29 lip 2026, 23:36 UTC

News

Antero Resources shares are lower in after-market trading following a second-quarter earnings report that included an adjusted EPS miss and mixed operational results.

29 lip 2026, 23:36 UTC

News

Peabody Energy announced a quarterly dividend of $0.075 per share after reporting $1 billion in revenue, despite a net loss of $90.6 million. Shares rose in after-market trading.

29 lip 2026, 23:32 UTC

News

Invitation Homes reported strong Q2 results, with net income rising to $218.2 million. Shares are trading higher in after-market hours following the earnings report.

29 lip 2026, 23:32 UTC

News

AXT Inc secures an $87 million supply agreement with Lumentum for indium phosphide wafers, boosting its strategic position in the semiconductor market during after-market hours.

29 lip 2026, 23:31 UTC

News

Saia Inc shares are higher in after-market trading as the company prepares to report earnings. It exceeded revenue expectations with $806.2 million last session.

29 lip 2026, 23:31 UTC

News

DMC Global Inc reported second-quarter sales of $157 million, exceeding estimates. Shares are trading higher in after-market hours following the results.

29 lip 2026, 23:31 UTC

Social Media
News

Lam Research Corp reported strong second-quarter earnings, with adjusted EPS of $1.82 and optimistic guidance for Q3, driving shares higher in after-market trading.

29 lip 2026, 23:31 UTC

News

iShares 7-10 Year Treasury Bond ETF trades lower in after-hours, reflecting market caution amid geopolitical tensions and concerns about rising interest rates and inflation.

29 lip 2026, 23:31 UTC

News

Vanguard Total Bond Market ETF declines in after-market trading amid rising geopolitical tensions and concerns over inflation and interest rates affecting market sentiment.

29 lip 2026, 23:31 UTC

News

RenaissanceRe Holdings increased its share buyback program to $750 million and declared a quarterly dividend of $0.41, driving shares higher in after-market trading.

29 lip 2026, 23:26 UTC

News

Ford Motor Co reported adjusted earnings of $0.42 per share, raising its 2026 guidance and prompting shares to rise in after-market trading.

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

68.6% upside

12 Months Forecast

Average 30.87 USD  68.6%

High 44 USD

Low 21.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

322 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat